Pharmaceutical intelligence for Adlai Nortye Biopharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalJuly 16, 2026

Adlai Nortye initiates trial for AN4035 in RAS-mutated advanced cancers

Adlai Nortye Biopharma is conducting a clinical trial to evaluate the safety and tolerability of AN4035 in patients with advanced solid tumors harboring RAS mutations and high CEACAM5 expression.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJuly 16, 2026

Adlai Nortye initiates trial for AN4035 in RAS-mutated advanced cancers

Adlai Nortye Biopharma is conducting a clinical trial to evaluate the safety and tolerability of AN4035 in patients with advanced solid tumors harboring RAS mutations and high CEACAM5 expression.

Competitive activity

No signals indexed for this entity yet.

Assets

AN4035 →

Therapeutic areas

Oncology →

RAS Mutations →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.